GILD

166.4300.06%
DP

Dietmar P. Berger

Chief Medical Officer

Dr. Dietmar P. Berger, M.D., Ph.D. was Director of Arcus Biosciences, Inc. from February 6, 2025 until 2026. He serves as Director at Transcelerate Biopharma, Inc. Dr. Berger is Chief Medical Officer of Gilead Sciences, Inc. from January 2, 2025. Dr. Berger is President of Inhibrx, Inc. since May 30, 2024. He served as Chief Medical Officer and Global Head of Development at Sanofi. Dr. Berger served as Deputy Chairman of supervisory Board at Raiffeisenbank Grimma eG until June 7, 2021. He was Board Observer at Abcuro, Inc. Dr. Berger had been Global Head of Research and Development at Atara Biotherapeutics, Inc. from May 2018 to May 31, 2019. Prior to joining Atara, Dr. Berger was Senior Vice President and Global Head, Product Development, Clinical Science Hematology and Oncology at Roche/Genentech. In this role, he led medical strategy for the company's global clinical development portfolio for cancer medicines, including global filings and approvals of Gazyva, Cotellic, Alecensa, Tecentriq and Hemlibra. Formerly, he was Vice President of Global Clinical Development for Roche/Genentech's HER2 breast cancer franchise, supporting the development and marketing approvals of Perjeta and Kadcyla across several new indications. Previously, he led oncology clinical development at Bayer and held positions of increasing responsibility at Amgen. Dr. Berger also led research groups focusing on preclinical and clinical drug development, tumor models, angiogenesis and immunotherapy as Head of the Clinical Research Center at the University Medical Hospital, Freiburg, Germany and at The Scripps Research Institute, La Jolla, CA. He is Professor of Medicine at the University of Freiburg Hospital in Freiburg. He received the Cancer Award of the German Cancer Society for his research on angiogenesis and earned his M.D. and Ph.D. degrees from the Albert-Ludwigs University School of Medicine (officially known as University of Freiburg. Dr. Berger is board certified in Internal Medicine, Hematology and Oncology.

Positions